EU HTA

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Meregaglia et al. explored the expected impact of implementing the EU HTA Regulation and Joint Clinical Assessment through a multi-stakeholder case study in Italy.

On June 3, 2026, the submission period opened for Joint Scientific Consultation (JSC) requests under the EU Health Technology Assessment Regulation (HTAR) framework. The deadline for submitting requests is July 1, 2026. JSCs offer health technology developers the opportunity to seek scientific advice on the information and evidence required for a potential future EU Joint Clinical Assessment.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Xander et al. examined the legal implications of Joint Clinical Assessments under the EU HTA Regulation, focusing on PICO disparities across Member States and conflict-of-interest management in expert involvement.

The EU Health Technology Assessment Regulation (HTAR) framework will host a webinar on June 19, 2026, aimed at providing clarity on the processes for joint clinical assessments (JCA) and joint scientific consultations (JSC) concerning high-risk medical devices and in vitro diagnostics (IVDs). Registration is now open

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Taylor et al. explored challenges and opportunities associated with incorporating real-world evidence into submissions under the EU’s new Joint Clinical Assessment process.

On April 1, 2026, the submission period for Joint Scientific Consultations (JSCs) requests under the EU Health Technology Assessment Regulation (HTAR) framework opened. JSCs offer health technology developers the opportunity to seek scientific advice on the information and evidence required for a potential future Joint Clinical Assessment. Requests related to both medical devices and medicines can be submitted until April 29, 2026.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Julian et al. developed a stakeholder-centric framework of key performance indicators to support implementation of the EU HTA Regulation across Europe using a modified Delphi approach.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, D'Oca et al. analyzed current practices in the PICO scoping process used to define the scope of Joint Clinical Assessments under the EU HTA Regulation.

On February 16, 2026, the Member State Coordination Group on HTA (HTACG) released its first annual report, detailing all activities of the group and its subgroups in 2025 within the joint EU-level HTA framework. The framework became fully operational on January 12, 2025, when Regulation (EU) 2021/2282 entered into application, creating a legal basis for Member States' cooperation on joint clinical assessments of medicines and medical devices.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Alshaikh et al. explored how national HTA bodies across 11 EU Member States are preparing for the implementation of the EU Health Technology Assessment Regulation (HTAR) and the introduction of Joint Clinical Assessments (JCAs) for high-risk medical devices and IVDs.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Dang et al. reviewed the implementation of Joint Clinical Assessments under the EU HTAR (Regulation 2021/2282), analyzing methodological, regulatory, and stakeholder implications across EU Member States.

In January 2026, the HTA Coordination Group published the report on Emerging Health Technologies identified in 2025 within the framework of the EU Regulation on Health Technology Assessment (HTAR). The report provides information on technologies (including 15 medical devices) that may be eligible for Joint Clinical Assessments (JCAs) at the EU level from 2026.